Agenus Inc.

Equities

AGEN

US00847G8042

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
17.7 ^USD	+13.46%		+13.61%	+6.90%

28/06	Sector Update: Health Care Stocks Edge Higher in Afternoon Trading	MT
28/06	Agenus Shares Rise After Trial Shows Tumor Reductions in Colon Cancer Patients	MT

Agenus to Participate at B Riley Securities' 2023 Virtual Oncology Conference

January 11, 2023 at 05:51 pm IST

Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O'Day, Chief Medical Officer, will participate in a virtual fireside chat at the B Riley Securities' 2023 Virtual Oncology Conference on Wednesday, January 18th at 11:30am ET.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs.

Contact:

Zack Armen

Tel: 917-362-1370

Email: zack.armen@agenusbio.com

Latest news about Agenus Inc.

Sector Update: Health Care Stocks Edge Higher in Afternoon Trading	28/06	MT
Agenus Shares Rise After Trial Shows Tumor Reductions in Colon Cancer Patients	28/06	MT
Agenus Inc Announces Results from an Investigator-Sponsored Trial of Botensilimab and Balstilimab (BOT/BALl) in the Neoadjuvant Setting for Colon Cancer	28/06	CI
Agenus Inc. Announces Availability of Botensilimab for Clinical Studies	27/06	CI
Agenus Appoints Jennifer Buell to Its Board of Directors	17/06	CI
Transcript : Agenus Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM	12/06
Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer	16/05	CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	07/05	MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	07/05	MT
Transcript : Agenus Inc., Q1 2024 Earnings Call, May 07, 2024	07/05
Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M	07/05	MT
Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Ligand and Agenus Enter into $100 Million Royalty Financing Agreement to Support Agenus? Key Development Initiatives in the Ongoing Bot/Bal Clinical Development Program	07/05	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	13/04	MT
Sector Update: Health Care	13/04	MT
Agenus Shares Decline After Update on Early Stage Colorectal Cancer Drug Trial	12/04	MT
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer	12/04	CI
Agenus Stockholders Approve 1-for-20 Reverse Stock Split	06/04	MT
B. Riley Securities Trims Agenus' Price Target to $5 From $6 After Model Update, Maintains Buy Rating	18/03	MT
Transcript : Agenus Inc., Q4 2023 Earnings Call, Mar 14, 2024	14/03
Earnings Flash (AGEN) AGENUS Posts Q4 Revenue $83.8M	14/03	MT
Agenus Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03	CI
Agenus Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03	CI
Agenus Inc. Announces Preclinical Data on BMS-986442 at AACR 2024	06/03	CI
Ginkgo Bioworks, Agenus Unit Win Contract to Discover, Develop Vaccine Adjuvants	15/02	MT

Chart Agenus Inc.

Duration

Period

More charts

Company Profile

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Agenus Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.7 USD

Average target price

44.25 USD

Spread / Average Target

+150.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AGENUS INC.	+6.90%	328M
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research